Clinical Research Directory
Browse clinical research sites, groups, and studies.
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
Sponsor: Ukko Inc
Summary
This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Official title: A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-02-18
Completion Date
2027-11-01
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
UKK-0018
UKK0018 is an immunotherapeutic treatment of peanut allergies
Locations (5)
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Flinders Medical Center
Bedford Park, South Australia, Australia
The Royal Melbourne Hospital
Fitzroy, Victoria, Australia
Fiona Stanley Hospital
Perth, Western Australia, Australia
Pacific Clinical Research Network - Auckland
Takapuna, Auckland, New Zealand